Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed) | PAR 20 029

Opportunity Information: Apply for PAR 20 029

The Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) funding opportunity (PAR 20-029) is a National Institutes of Health (NIH) discretionary grant program that uses the R01 research project grant mechanism and explicitly does not allow clinical trials under this announcement. Its central aim is to move the field toward longer-acting HIV drug delivery approaches by supporting research that develops and advances sustained-release strategies for either HIV treatment or HIV prevention. The overarching public health motivation behind the program is to improve real-world effectiveness of antiretroviral drugs by reducing dosing frequency, which can help address adherence barriers that often limit outcomes in both treatment and pre-exposure prophylaxis (PrEP) settings.

The scientific scope emphasizes formulation and delivery solutions that can maintain effective antiviral drug levels over extended periods. Applicants may propose sustained-release products for treatment or prevention delivered through multiple platform types, including oral sustained-release formulations, long-acting injections, implants, or approaches that deliver drug directly to HIV target mucosal tissues. The FOA sets minimum duration expectations that effectively define what NIH considers meaningfully "sustained" in this context: for oral treatment approaches, the product should provide at least one week of coverage, while for all other delivery systems (including injections, implants, and mucosal delivery approaches) the product should provide at least monthly dosing for both prevention and treatment. In practical terms, this means the program is looking for strategies that credibly shift antiretroviral administration from daily or frequent dosing toward weekly oral regimens or monthly-or-longer non-oral modalities, with the intent of supporting durable drug exposure profiles that match the biology and pharmacology needed to suppress or prevent HIV infection.

From an eligibility standpoint, the announcement is broad and inclusive, allowing applications from many organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments that are federally recognized; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; and small businesses. The opportunity also highlights additional eligible applicant categories that NIH often calls out to encourage participation from diverse institution types and communities, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This breadth signals that NIH is open to a wide range of teams, including those with specialized capabilities in drug delivery, formulation science, biomaterials, pharmacokinetics, and HIV prevention science.

Administratively, the opportunity is categorized under Health (CFDA 93.855) and is offered as a grant. The source data lists an original closing date of January 7, 2022, and the record creation date as October 10, 2019. The award ceiling and expected number of awards are not specified in the provided source excerpt, which typically means applicants would need to consult the full FOA text or NIH program contacts for the most current budget and award information, as well as any institute- or center-specific priorities. Overall, the opportunity is designed to fund research that can materially extend how long HIV antivirals remain effective in the body or at relevant mucosal sites, using delivery technologies that support weekly oral treatment or monthly-or-longer dosing for other modalities, while staying within a non-clinical-trial R01 research framework.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2019-10-10.
• Applicants must submit their applications by 2022-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 20 029

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: